Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke

2008965 citationsJournal Articlebronze Open Access

Authors

Ralph L. Sacco · University of Miami

Hans‐Christoph Diener · Boehringer Ingelheim (Canada)

Salim Yusuf · Population Health Research Institute

Otto W. Witte · Boehringer Ingelheim (Canada)

Stephanie Ôunpuu · Boehringer Ingelheim (Canada)

William A Lawton · Boehringer Ingelheim (Canada)

Yuko Palesch

Abstract

The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.)

Topics & Keywords

Antiplatelet Therapy and Cardiovascular Diseases Acute Ischemic Stroke Management Cerebrovascular and Carotid Artery Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 359, Issue 12, pp. 1238-1251

DOI: 10.1056/nejmoa0805002

Field-Weighted Citation Impact: 54.91